ProteoTech Inc., is a private drug development Company founded in 1996 that is located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. ProteoTech is utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes and systemic amyloidosis.

With over 165 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1^® for the treatment of mild-to-moderate Alzheimer's disease.

The Company is in late stage pre-clinical development with Synuclere^™ for the treatment of Parkinson's disease, and Systebryl^™ for the treatment of Systemic Amyloidosis. ProteoTech is also in late stage pre-clinical development for a novel small peptide called PeptiClere^™ as a nasal spray for the treatment of Alzheimer's disease. ProteoTech is additionally developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes.

ProteoTech International Alzheimer's Conference Presentation - Exebryl-1® Download Poster (PDF)	ProteoTech International Alzheimer's Conference Presentation - PeptiClere™ Download Poster (PDF)
ProteoTech's Alzheimers Target:Beta-amyloid Protein	ProteoTech's Parkinson's Target:Alpha-synuclein
Human Alzheimer's brain filled with amyloid plaques (arrows) (click image to enlarge)	Neuron in the substantia nigra with a Lewy body containing alpha-synuclein (click image to enlarge)
ProteoTech's Type 2 Diabetes Target:Islet Amyloid Polypeptide	ProteoTech's Systemic AA Amyloidosis Target:Systemic AA Amyloidosis
Congo red staining of IAPP amyloid deposits in Islet of Langerhans (pancreas) of patient with Type 2 Diabetes (click image to enlarge)	Systemic AA amyloid deposits in liver (click image to enlarge)